Innate Immunotherapeutics Ltd. is changing its name to Amplia Therapeutics Ltd.
The Australian pharmaceutical company will also change its stock code to ATX from IIL. Shareholders approved the changes at their annual general meeting in August.
The company said the changes are part of a wider branding refresh, as it focuses on therapeutic targets called focal adhesion kinase inhibitors. These can sensitize certain tumors to cancer drugs and chemotherapies.
Recently, the company found itself at the center of a U.S. congressman's insider trading scandal.